Jobs
View more job listings or post a job
Bioduro-Sundia Associate Director/Director in Laboratory Animal and Exploratory Toxicology
Variant Bio (Senior) Scientist - DMPK
Alturas Analytics Scientist 1
University of California, Davis TOXICOLOGY ANALYTICAL CHEMIST (STAFF RESEARCH ASSOCIATE 3)
University of California, Davis CALIFORNIA ANIMAL HEALTH AND FOOD SAFETY LABORATORY - TOXICOLOGY LAB RESEARCH SUPERVISOR/GROUP LEADER
Eli Lilly and Company R-39973 Scientific Director ADME - Novel Modalities (Open)
FibroGen Director DMPK
Applied BioMath Technical Marketing Specialist
Horizon Therapeutics Director, Bioanalytical Sciences
Exelixis Principal Scientist - DMPK
Post a job

Workshop

Physiologically Based Pharmacokinetic Modeling (PBPK) in Drug Discovery and Development: Industry Examples and Regulatory Perspective


Speakers: Hannah Jones (Pfizer), Patrick Trapa (Pfizer), Karen Rowland-Yeo (Simcyp), Manthena Varma (Pfizer) Chirag Patel (Takeda Pharmaceuticals), Dhaval K. Shah (The State University of New York at Buffalo) and Ping Zhao (FDA)
Organizers: Andy Zhu (Takeda Pharmaceuticals)
Date: 2016-10-03
Time: 8:30-16:30 Eastern Time
Registration fee: (USD): Regular: $175; For Academic / unemployed: $125
Location: Courtyard by Marriott Boston Cambridge, 777 Memorial Dr, Cambridge, MA 02139
Major Sponsor:
Vendor show vendors registered to date:
Registration: http://www.PBSS.org
Registration deadline:2016-09-29  (it will close sooner if the seating cap is reached)

About the Topic

Workshop Description:

The application of physiologically based pharmacokinetic (PBPK) modeling is rapidly expanding within the pharmaceutical industry and has become an important part of drug discovery and development. At this workshop, experts from industry, academia and the FDA will discuss the fundamentals of PBPK, its application at different stages of drug development, and case examples as well as current challenges.

Agenda:

The following topics will be discussed:

  • An overview of the application of PBPK in an industry setting: confidence, limitations, and challenges.
  • Case studies of using PBPK to predict complex DDI and pharmacokinetic differences in special populations
  • Integrating PBPK with PopPK – the impact of PBPK on oncology drug development from a clinical pharmacology perspective
  • Application of PBPK modeling for transporter related human PK projections and DDI predictions
  • Mechanistic modeling of monoclonal antibodies and antibody-drug conjugate
  • FDA’s perspective on the application of PBPK in drug discovery and development


2024-06-25, [In-Person] Preclinical development and IND filing for small molecules: Nuts, Bolts and Best Practices
2024-06-25, [Webcast from Boston-PBSS] Preclinical development and IND filing for small molecules: Nuts, Bolts and Best Practices
©Pharmaceutical & BioScience Society, International; Last Modified: 4/16/2024; Admin Logon
Ads (in random order)
Submit a Text Ad
($250 for 2 months)

Lena Biosciences Predictive toxicology. Mitochondrial toxicity in a drug metabolism-competent model with active transporters. Intrinsic & idiosyncratic DILI.
Lena Biosciences Predictive toxicology. Intrinsic & idiosyncratic drug-induced liver injury. Mitochondrial toxicity in a drug metabolism-competent model.
Alturas Analytics, Inc. Expert Regulated & Non-Regulated LC-MS, GC-MS bioanalytical & PK/TK analysis of small & large molecules in any matrix. Discovery through phase IV.
Submit a Text Ad